Pairing Cancer Biomarkers to Biomedicine
Sign Up to like & getrecommendations! Published in 2017 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2017.10.025
Abstract: On May 23, 2017, the US Food and Drug Administration (FDA) approved pembrolizumab for the treatment of any solid tumors with certain specific genetic features or biomarkers, namely microsatellite instability-high (MSI-H) or mismatch repair deficient… read more here.
Keywords: cancer patients; biomarkers biomedicine; treatment; pairing cancer ... See more keywords